PHARMACEUTICAL FORMULATION 514

The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-be nzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone....

Full description

Saved in:
Bibliographic Details
Main Authors MICHAEL KARL BECHTOLD, KIERAN JAMES LENNON, KATJA MAREN FASTNACHT, JULIE KAY CAHILL, BENEDIKT STEITZ, CLAUDIA BETTINA HAEUSER, BERN HARALD LIEPOLD
Format Patent
LanguageEnglish
Spanish
Published 02.05.2011
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-be nzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-be nzyl]-2H- phthalazin-1-one for increasing the bioavailability of the drug. La presente invención se refiere a una formulación farmacéutica que contiene el fármaco 4-[3-(4-ciclopropanocarbonil-piperazina-1- carbonil)-4-fluorobencil]-2H-ftalazin-1-ona en una dispersión sólida con un polímero de matriz que tiene baja higroscopicidad y elevada temperatura de ablandamiento, como copovidona. La invención también se refiere a una dosis farmacéutica diaria del fármaco provisto por dicha formulación. Además, la invención se refiere al uso de un polímero de matriz que tiene baja higroscopicidad y elevada temperatura de ablandamiento en una dispersión sólida con 4-[3-(4-ciclopropanocarbonil-piperazina-1-ca rbonil)-4-fluorobencil]-2H-ftalazin-1-ona para aumentar la biodisponibilidad del fármaco.
Bibliography:Application Number: MX20110003740